Intellectus Partners LLC Increases Stake in Eli Lilly and Company (NYSE:LLY)

Intellectus Partners LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 153.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,077 shares of the company’s stock after purchasing an additional 652 shares during the period. Intellectus Partners LLC’s holdings in Eli Lilly and Company were worth $832,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in LLY. Principal Financial Group Inc. raised its holdings in Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after buying an additional 60,306 shares during the last quarter. Fiera Capital Corp raised its holdings in Eli Lilly and Company by 2.3% during the 3rd quarter. Fiera Capital Corp now owns 23,172 shares of the company’s stock valued at $20,529,000 after buying an additional 524 shares during the last quarter. Leavell Investment Management Inc. raised its holdings in Eli Lilly and Company by 2.1% during the 3rd quarter. Leavell Investment Management Inc. now owns 6,130 shares of the company’s stock valued at $5,431,000 after buying an additional 124 shares during the last quarter. AEGON ASSET MANAGEMENT UK Plc raised its holdings in Eli Lilly and Company by 0.9% during the 3rd quarter. AEGON ASSET MANAGEMENT UK Plc now owns 78,186 shares of the company’s stock valued at $69,221,000 after buying an additional 709 shares during the last quarter. Finally, Equitable Trust Co. raised its holdings in Eli Lilly and Company by 0.3% during the 3rd quarter. Equitable Trust Co. now owns 8,540 shares of the company’s stock valued at $7,566,000 after buying an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $868.59 on Friday. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company’s 50-day moving average is $826.63 and its 200 day moving average is $847.97. The company has a market capitalization of $823.57 billion, a price-to-earnings ratio of 74.17, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 51.24%.

Eli Lilly and Company announced that its Board of Directors has initiated a share repurchase plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a report on Friday, January 17th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, Bank of America restated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,007.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.